Please ensure Javascript is enabled for purposes of website accessibility

Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward

By Dan Caplinger - Updated Apr 26, 2021 at 2:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nasdaq gained ground to start the week.

Stock markets were mixed on Monday afternoon as investors tried to consider all the crosscurrents on Wall Street right now. It was a great day for the Nasdaq Composite (^IXIC 0.00%), however, which was up three-quarters of a percent as of 1:45 p.m. EDT today and challenging its all-time highs.

Two areas that have been supporting the Nasdaq greatly in recent months have been technology and biotech. In the semiconductor space, Skyworks Solutions (SWKS -1.64%) got a big boost today as investors await earnings later this week. Meanwhile, biotech company CRISPR Therapeutics (CRSP 4.97%) saw solid gains as it gave an update on its pipeline.

Lab tech holding a chip in a gloved hand.

Image source: Getty Images.

Heading Sky-ward

Skyworks Solutions saw its stock rise almost 5% Monday afternoon. The company continued to make progress following favorable news recently.

The good news for Skyworks started last week, when the company announced it would pay $2.75 billion to acquire assets from Silicon Laboratories (SLAB -8.44%). The cash deal will help Skyworks get greater exposure to some areas with high growth potential, particularly the autonomous-vehicle end of the automotive sector. Skyworks expects the acquisition will immediately boost earnings.

Subsequently, a host of analysts weighed in favorably on the move, with B. Riley giving a minimal boost to its price target on Friday. UBS joined in with a price target bump on Monday, although it kept its rating on the stock at neutral.

Skyworks' efforts to diversify its business are important, as it remains dangerously exposed to its agreements with Apple (AAPL 1.62%). That's been problematic for Skyworks stock in the past, and if deals like the Silicon Labs acquisition can help protect the company from the ups and downs of Apple's fortunes, many shareholders would appreciate it.

Looking crispy

CRISPR Therapeutics saw its stock do even better, rising almost 7%. Unlike Skyworks, that's still far below its all-time highs, but investors are feeling a little more upbeat about the gene-editing specialist's prospects.

CRISPR announced that it and partner Vertex Pharmaceuticals (VRTX 1.96%) received priority medicines designation from European regulators for its CTX001 gene-edited therapy for treating transfusion-dependent beta thalassemia. CTX001 had previously received similar designation for treating patients suffering from sickle cell disease. In addition, the Food and Drug Administration had already awarded a host of designations to CTX001, including both orphan-drug and fast-track status.

Vertex and CRISPR have been deepening their relationship lately, with provisions that guarantee more money for CRISPR and put more risk on Vertex. Given how much larger Vertex is, that's potentially good for both parties, although it might limit CRISPR's upside.

Many investors are highly optimistic about the prospects that gene-editing technology has to revolutionize healthcare and allow for customized treatments that take specific traits of individual patients into account. CRISPR isn't the only stock in that area, but with the potential for treatments covering a wider range of conditions in the future, the company has plenty of reasons for investors to feel confident about the months and years to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Skyworks Solutions, Inc. Stock Quote
Skyworks Solutions, Inc.
$91.12 (-1.64%) $-1.52
Apple Inc. Stock Quote
Apple Inc.
$138.93 (1.62%) $2.21
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$11,028.74 (0.00%) $0.00
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$287.32 (1.96%) $5.53
Silicon Laboratories Inc. Stock Quote
Silicon Laboratories Inc.
$128.39 (-8.44%) $-11.83
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$63.79 (4.97%) $3.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.